- Home
- THRM vs CVAC Comparison
THRM vs CVAC Comparison
Compare THRM & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THRM | CVAC |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | THRM | CVAC |
|---|---|---|
| Price | $35.84 | $5.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $39.00 | $6.83 |
| AVG Volume (30 Days) | 172.0K | ★ 1.3M |
| Earning Date | 10-23-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.02 |
| EPS | ★ 0.99 | 0.94 |
| Revenue | ★ $1,468,728,000.00 | $83,000,117.00 |
| Revenue This Year | $3.56 | N/A |
| Revenue Next Year | $2.52 | $23.40 |
| P/E Ratio | $35.96 | ★ $5.86 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.75 | $2.48 |
| 52 Week High | $43.99 | $5.72 |
Technical Indicators
Market Signals| Indicator | THRM | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 64.99 |
| Support Level | $32.60 | $4.95 |
| Resistance Level | $36.62 | $5.39 |
| Average True Range (ATR) | 1.20 | 0.11 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 54.45 | 94.17 |
Price Performance
Historical ComparisonAbout THRM Gentherm Inc
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the United States, China, South Korea, Germany, Japan, the Czech Republic, and other countries.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.